NBIO Stock Overview
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nascent Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.096 |
| 52 Week High | US$0.28 |
| 52 Week Low | US$0.032 |
| Beta | -3.2 |
| 1 Month Change | -30.29% |
| 3 Month Change | -19.75% |
| 1 Year Change | 91.00% |
| 3 Year Change | 21.19% |
| 5 Year Change | -13.96% |
| Change since IPO | -90.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| NBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.5% | -4.2% | -3.7% |
| 1Y | 91.0% | -2.0% | 20.5% |
Return vs Industry: NBIO exceeded the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: NBIO exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| NBIO volatility | |
|---|---|
| NBIO Average Weekly Movement | 22.6% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NBIO's share price has been volatile over the past 3 months.
Volatility Over Time: NBIO's weekly volatility (23%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Sean Carrick | www.nascentbiotech.com |
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation.
Nascent Biotech, Inc. Fundamentals Summary
| NBIO fundamental statistics | |
|---|---|
| Market cap | US$16.29m |
| Earnings (TTM) | -US$2.09m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.8x
P/E RatioIs NBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NBIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$138.20k |
| Gross Profit | -US$138.19k |
| Other Expenses | US$1.95m |
| Earnings | -US$2.09m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 411.6% |
How did NBIO perform over the long term?
See historical performance and comparison